SHH and neoplasm: The SHH-antagonist HH-Antag induces bone defects when administered to young tumor prone mice [23] and a patient treated with the SHH-antagonist GDC-0449 became resistant to the drug due to mutations in the targeted receptor Smoothened (SMO) [24].